MX2016007658A - Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl. - Google Patents
Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl.Info
- Publication number
- MX2016007658A MX2016007658A MX2016007658A MX2016007658A MX2016007658A MX 2016007658 A MX2016007658 A MX 2016007658A MX 2016007658 A MX2016007658 A MX 2016007658A MX 2016007658 A MX2016007658 A MX 2016007658A MX 2016007658 A MX2016007658 A MX 2016007658A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- prevention
- treatment
- hdl cholesterol
- cholesterol level
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 230000006806 disease prevention Effects 0.000 title abstract 2
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- -1 methyl cyclodextrin Chemical compound 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se refiere a nuevo uso de una composición farmacéutica que comprende al menos una metil ciclodextrina que tiene un grado de sustitución molar (MS) entre 0.05 y 1.5 en el tratamiento y/o prevención de enfermedades que pueden tratarse y/o prevenirse mediante un aumento en el nivel de colesterol HDL. La invención también se refiere al uso de la misma en el tratamiento y/o prevención de la aterosclerosis o complicaciones relacionadas con un ateroma, y/o enfermedades del sistema nervioso central. Las composiciones farmacéuticas de la invención también pueden usarse para estimular la reducción de los niveles en circulación de ácidos grasos y triglicéridos y para reducir o prevenir las placas ateromatosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1362633A FR3014694B1 (fr) | 2013-12-13 | 2013-12-13 | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| PCT/FR2014/053309 WO2015087016A1 (fr) | 2013-12-13 | 2014-12-12 | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007658A true MX2016007658A (es) | 2016-09-26 |
Family
ID=50424476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007658A MX2016007658A (es) | 2013-12-13 | 2014-12-12 | Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10022392B2 (es) |
| EP (2) | EP3082831B1 (es) |
| JP (2) | JP6322289B2 (es) |
| KR (3) | KR20160088874A (es) |
| CN (2) | CN105792833B (es) |
| AU (2) | AU2014363270B2 (es) |
| BR (1) | BR112016013481A2 (es) |
| CA (2) | CA2930489C (es) |
| DK (1) | DK3082831T3 (es) |
| ES (1) | ES2859609T3 (es) |
| FR (1) | FR3014694B1 (es) |
| MX (1) | MX2016007658A (es) |
| PL (1) | PL3082831T3 (es) |
| RU (1) | RU2677889C1 (es) |
| WO (2) | WO2015087017A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| EP3307278A4 (en) | 2015-06-10 | 2018-06-13 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| FR3042501B1 (fr) * | 2015-10-16 | 2017-11-03 | Roquette Freres | Nouvelles cyclodextrines methylees et leurs procedes de preparation |
| WO2017163128A2 (en) * | 2016-03-20 | 2017-09-28 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
| CA3030142A1 (en) * | 2016-07-08 | 2018-01-11 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases |
| KR101906578B1 (ko) * | 2017-07-28 | 2018-10-10 | 경북대학교 산학협력단 | 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물 |
| AU2018341235A1 (en) | 2017-09-28 | 2020-05-07 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| CN107982546A (zh) * | 2017-12-05 | 2018-05-04 | 中国药科大学 | 基于主客体相互作用的酸敏感超分子纳米粒及其应用 |
| US12089930B2 (en) | 2018-03-05 | 2024-09-17 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| CN108342473A (zh) * | 2018-04-13 | 2018-07-31 | 东华大学 | 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒 |
| KR20210027279A (ko) * | 2018-06-29 | 2021-03-10 | 로께뜨프레르 | 신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법 |
| FR3083234B1 (fr) * | 2018-06-29 | 2020-11-27 | Roquette Freres | Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation |
| JP7446322B2 (ja) * | 2018-10-29 | 2024-03-08 | シクロ セラピューティクス インク | アルツハイマー病を治療する方法 |
| WO2020142716A1 (en) * | 2019-01-03 | 2020-07-09 | Sens Research Foundation, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| US11446325B2 (en) * | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| FR3115682B1 (fr) * | 2020-11-05 | 2023-02-24 | Roquette Freres | Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique |
| KR20240148426A (ko) * | 2022-02-18 | 2024-10-11 | 베렌 테라퓨틱스 피.비.씨. | 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료 |
| AU2023220047A1 (en) | 2022-02-18 | 2024-09-19 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265230A (ja) * | 1986-05-12 | 1987-11-18 | Kao Corp | 高脂血症治療・予防剤 |
| BE1006873A6 (nl) * | 1993-03-26 | 1995-01-10 | Merkus Franciscus W H M | Toedieningsformulering voor nasale insuline toediening. |
| ATE320803T1 (de) | 1998-01-28 | 2006-04-15 | Warner Lambert Co | Verfahren zur behandlung von alzheimerschen krankheit |
| US6602860B1 (en) | 1999-11-12 | 2003-08-05 | Josef Pitha | Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| WO2001080715A2 (en) * | 2000-04-21 | 2001-11-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying compounds useful for preventing acute clinical vascular events in a subject |
| AUPR178300A0 (en) * | 2000-11-29 | 2000-12-21 | Heart Research Institute Ltd., The | Cyclodextrins and reversal of atherosclerosis |
| TW200307011A (en) * | 2002-04-18 | 2003-12-01 | Chugai Pharmaceutical Co Ltd | Hyaluronic acid modifier |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| BRPI0515191A (pt) * | 2004-08-13 | 2008-07-08 | Angiotech Internac Ag | composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico |
| GB0421176D0 (en) * | 2004-09-23 | 2004-10-27 | Poston Robin | Treatment of atherosclerosis |
| US9034846B2 (en) * | 2004-10-10 | 2015-05-19 | Universite De Liege | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases |
| EP1655034A1 (en) | 2004-10-10 | 2006-05-10 | Université de Liège | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases. |
| US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| TW201006463A (en) * | 2008-06-26 | 2010-02-16 | Merz Pharma Gmbh & Co Kgaa | Pharmaceutical compositions comprising aminocyclohexane derivatives |
-
2013
- 2013-12-13 FR FR1362633A patent/FR3014694B1/fr active Active
-
2014
- 2014-12-12 MX MX2016007658A patent/MX2016007658A/es unknown
- 2014-12-12 JP JP2016538683A patent/JP6322289B2/ja active Active
- 2014-12-12 PL PL14827505T patent/PL3082831T3/pl unknown
- 2014-12-12 CN CN201480065300.6A patent/CN105792833B/zh active Active
- 2014-12-12 DK DK14827505.0T patent/DK3082831T3/da active
- 2014-12-12 WO PCT/FR2014/053310 patent/WO2015087017A1/fr active Application Filing
- 2014-12-12 US US15/039,864 patent/US10022392B2/en active Active
- 2014-12-12 CN CN201910316561.5A patent/CN110123831A/zh active Pending
- 2014-12-12 EP EP14827505.0A patent/EP3082831B1/fr active Active
- 2014-12-12 EP EP19184268.1A patent/EP3581188A1/fr active Pending
- 2014-12-12 KR KR1020167013320A patent/KR20160088874A/ko not_active IP Right Cessation
- 2014-12-12 CA CA2930489A patent/CA2930489C/fr active Active
- 2014-12-12 RU RU2016128411A patent/RU2677889C1/ru active
- 2014-12-12 BR BR112016013481-8A patent/BR112016013481A2/pt not_active Application Discontinuation
- 2014-12-12 KR KR1020217042008A patent/KR102463677B1/ko active IP Right Grant
- 2014-12-12 AU AU2014363270A patent/AU2014363270B2/en active Active
- 2014-12-12 ES ES14827505T patent/ES2859609T3/es active Active
- 2014-12-12 WO PCT/FR2014/053309 patent/WO2015087016A1/fr active Application Filing
- 2014-12-12 CA CA3180528A patent/CA3180528A1/fr active Pending
- 2014-12-12 KR KR1020217017348A patent/KR102453643B1/ko active IP Right Grant
-
2018
- 2018-02-23 US US15/903,738 patent/US11266680B2/en active Active
- 2018-04-06 JP JP2018073664A patent/JP2018123153A/ja active Pending
-
2020
- 2020-01-23 AU AU2020200500A patent/AU2020200500B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007658A (es) | Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl. | |
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| SG10201907660YA (en) | Use of short chain fatty acids in cancer prevention | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| MX2018005096A (es) | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| MX2015001250A (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| EP4218743A3 (en) | Compositions for use in cartilage breakdown | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| WO2016149659A3 (en) | Antisense-induced exon exclusion in myostatin | |
| SG10201909382UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| EP4041209A4 (en) | TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS | |
| PH12016501159A1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| MX2015012720A (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| WO2014108337A8 (en) | Pyrazolyl-based carboxamides i as crac channel inhibitors | |
| MX2013015419A (es) | Dha y epa en la reduccion de estres oxidante. | |
| MX2013002119A (es) | Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3. | |
| WO2014108336A8 (en) | Pyrazolyl-based carboxamides ii as crac channel inhibitors | |
| WO2015017383A3 (en) | Compositions and methods of the treatment of fatty acid metabolism disorders |